FDA calls for more research into erythropoiesis-stimulating agents | HemOncToday Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Tuesday, January 12, 2010

FDA calls for more research into erythropoiesis-stimulating agents | HemOncToday



"PERSPECTIVE

It should be emphasized that the FDA release focuses solely on patients with chronic renal disease, not cancer. It's a different population, so nothing in this release applies to the anemia of chemotherapy or patients with myelodysplastic syndrome. Right now, the ASCO/ASH ESA guideline committee is looking at present data to see if they need to make any modifications in the guidelines for the use of ESAs. The NCCN modified its guideline about a year ago and agree with the FDA recommendations that ESAs shouldn't be used in a standard fashion in patients being treated for curative intent. That's become standard of care, and for patients on chemotherapy, nothing has changed in the past year.

- Samuel Silver, MD, PhD
HemOnc Today Editorial Board member"

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.